Clinical Trial Update: PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 [Phase 3]

View source ↗

Summary

A Phase 3 trial of PH94B nasal spray for anxiety triggered by public speaking in adults with Social Anxiety Disorder was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Social Anxiety Disorder

Drugs mentioned

• PH94B Nasal Spray (PH94B)

Snippet

Sponsor: VistaGen Therapeutics, Inc. | Conditions: Social Anxiety Disorder | Phase 3 | Status: TERMINATED | Results posted: 2025-11-24